Development of a validated LC-MS/MS method for quantification of phosphoinositide 3 kinase inhibitor GSK2636771: Application to a pharmacokinetic study in rat plasma

J Pharm Biomed Anal. 2020 Feb 5:179:112950. doi: 10.1016/j.jpba.2019.112950. Epub 2019 Nov 16.

Abstract

A simple and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) coupled with one-step protein precipitation extraction method was developed and validated for determination of GSK2636771, a phosphoinositide 3 kinase (PI3K) inhibitor in rat plasma. After protein precipitation with acetonitrile, the chromatographic separation was carried out on a CORTECS UPLC C18 column, with acetonitrile and 0.1 % formic acid in water as mobile phase at a flow rate of 0.30 mL·min-1. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode via electrospray ionization (ESI) source, with target quantitative ion pairs of m/z 434.2→416.2 for GSK2636771, and 411.2→367.2 for BKM120 (internal standard). The calibration curve was linear over the range of 2.0-8000 ng·mL-1, and the LLOQ was evaluated to be 2.0 ng·mL-1. The accuracy (relative error, RE %) ranged from -3.4 % to 4.7 %, and the intra- and inter-day precision were within 15 %, and with the mean extraction recovery 82.1-89.3 %. The validated method described a quantification method of GSK2636771 in detail for the first time and applied to a pharmacokinetic study after oral administration of GSK2636771 at low, medium and high doses in rats. The mean plasma concentration versus time profiles of GSK2636771 showed a dose-dependent relationship at different doses.

Keywords: GSK2636771; LC–MS/MS; Pharmacokinetics; Phosphoinositide 3 kinase.

Publication types

  • Validation Study

MeSH terms

  • Administration, Oral
  • Animals
  • Chromatography, Liquid / methods*
  • Dose-Response Relationship, Drug
  • Imidazoles / administration & dosage
  • Imidazoles / analysis*
  • Imidazoles / pharmacokinetics
  • Male
  • Morpholines / administration & dosage
  • Morpholines / analysis*
  • Morpholines / pharmacokinetics
  • Phosphoinositide-3 Kinase Inhibitors / administration & dosage
  • Phosphoinositide-3 Kinase Inhibitors / analysis*
  • Phosphoinositide-3 Kinase Inhibitors / pharmacokinetics
  • Rats
  • Rats, Wistar
  • Tandem Mass Spectrometry / methods*

Substances

  • Imidazoles
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • GSK2636771